索拉非尼治疗肝细胞癌的现状  

The current status of sorafenib treatment in hepatocellular carcinoma

作　　者：梁博[1] 刘萧[1] 杨定华[1] 

机构地区：[1]南方医科大学附属南方医院肝胆外科,广州510515

出　　处：《实用肿瘤学杂志》2014年第3期280-284,共5页Practical Oncology Journal

摘　　要：在我国肝细胞癌有较高的发病率、术后复发率和病死率。肝细胞癌对放化疗不敏感，尤其是进展期肝细胞癌尚缺乏有效的治疗手段。索拉非尼是第一个用于肝细胞癌临床治疗的分子靶向药物，是肝细胞癌药物治疗的里程碑。然而，在临床应用中存在耐药现象。因此，探究索拉非尼的耐药机制、寻找耐药的分子标记物有重要意义。本文对索拉非尼治疗肝细胞癌的现状进行综述。Hepatocellular carcinoma（HCC）has high incidence rate,recurrence rate after surgecal treat-ment,as well as fatality rate in China .HCC is not sensitive to radiotherapy or chemotherapy and no effective treat-ment is available for HCC patients at advanced stage .Sorafenib is the first effective molecularly targeted drug for the treatment of HCC,which represents a milestone in the treatment of HCC .However,it also shows drug resist-ance during clinical application .Therefore,it is important to investigate the mechanism of drug resistance and its molecular markers for HCC .In this review ,we summarize the current status of the studies in these fields .

关 键 词：肝细胞癌 索拉非尼 进展期 耐药 

分 类 号：R657.3[医药卫生—外科学]